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Abstract
AAV1 and AAV6 are two closely related AAV serotypes. In the present study, we found AAV6
was more efficient in transducing mouse lower airway epithelia in vitro and in vivo than AAV1.
To further explore the mechanism of this difference, we found that significantly more AAV1
bound to mouse airway epithelia than AAV6, yet transduction by AAV6 was far superior. Lectin
competition assays demonstrated that both AAV1 and AAV6 similarly utilize α-2, 3-, and to a
lesser extend α-2, 6- linked sialic acids as the receptors for transduction. Furthermore, the rates of
AAV endocytosis could not account for the transduction differences of AAV1 and AAV6. Finally,
it was revealed that AAV6 was less susceptible to ubiquitin/proteasome-mediated blocks than
AAV1 when transducing mouse airway epithelia. Thus compared with AAV1, AAV6 has a unique
ability to escape proteasome-mediated degradation, which is likely responsible for its higher
transduction efficiency in mouse airway epithelium.
Introduction
AAV is a non-pathogenic human parvovirus with a single-stranded DNA genome of 4.7 kb
encapsidated in an icosahedral protein shell of ~ 25 nm in diameter (Berns and Giraud,
1996). Following the establishment of the first recombinant clone of AAV serotype 2
(AAV2) in 1982 (Samulski et al., 1983), AAV2 vectors have rapidly gained popularity in
gene therapy applications, thanks to their low pathogenicity, the ability to transduce non-
dividing cells, and the ability to establish long-term transgene expression. However, clinical
applications of AAV vectors (Berns and Giraud, 1996; Ding et al., 2005; Samulski et al.,
1983) have been impeded by its restricted cell/tissue tropism, low efficiency of in vivo gene
delivery, delayed onset of gene expression, and prevalent pre-existing neutralizing
© 2011 Elsevier Inc. All rights reserved.
Corresponding Author: R. Jude Samulski, CB # 7352, Gene Therapy Center, 7113 Thurston Building, The University of North
Carolina at Chapel Hill, Chapel Hill, NC 27599-7352, Tel. No: 919-962-3285, Fax No: 919-966-0907, rjs@med.unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Virology. Author manuscript; available in PMC 2012 September 1.
Published in final edited form as:













antibodies in the human populations. Twelve AAV serotypes --AAV1 through 12-- and over
one hundred variants have been isolated from tissue samples of human, non-human
primates, and other species (Gao, Vandenberghe, and Wilson, 2005; Mori et al., 2004;
Schmidt et al., 2008). The tissue tropisms of the different serotypes vary greatly due to the
structural diversity of their capsid proteins. The identification of suitable AAV serotypes for
specific tissues/cell types is highly desirable and has been pursued intensely in the past
decade (Gao, Vandenberghe, and Wilson, 2005; Louboutin, Wang, and Wilson, 2005).
Major efforts are focused on modifying capsid proteins to improve the transduction
efficiency and/or specificity of AAV-based vectors by rational design and directed evolution
(Asokan et al., 2010; Li et al., 2008; Li et al., 2009). The design of tissue-targeted capsid
constructs will likely expand and complement the current range of AAV serotypes and
variants.
Among all the serotypes, rAAV6 appeared to be a very promising gene delivery vector for
the lung. It was isolated as a contaminant of an adenovirus type 5 stock and is now believed
to be either a variant of AAV1, with more than 99% amino acid homology between their
capsids (Halbert et al., 2000; Rutledge, Halbert, and Russell, 1998), or a natural recombinant
between AAV1 and AAV2 (Xiao et al., 1999). It was reported thatα -2,3 and α-2,6 sialic
acids present on N-linked glycoproteins act as the primary receptors for AAV1 and AAV6
in multiple cell types by mediating viral attachment and infection (Wu et al., 2006b). AAV6
vectors have been shown to mediate higher in vivo transduction in the lung(Halbert, Allen,
and Miller, 2001), skeletal muscle(Blankinship et al., 2004), and liver (Wu et al., 2006a)
than AAV2 or AAV1 vectors. Gregorevic et al. reported that systemic intravenous
administration of high dose AAV6 vectors transduced cardiac and skeletal muscle efficiently
in mice (Blankinship et al., 2004). Kawamoto S et al. demonstrated the significant potential
of AAV6 serotype vectors for early gene expression and widespread regional transduction in
myocardium (Kawamoto et al., 2005). These results suggest that AAV6 is a promising
vector for gene delivery in vivo. However, the mechanism for the enhanced transduction of
AAV6 in these tissues has not yet been elucidated.
The effectiveness of rAAVs in gene delivery can be blocked at any of the steps, including
the physical binding to the target cells, receptor-mediated endocytosis, vesicular trafficking,
endosomal escape, and nuclear import, etc.. Understanding the key step(s) hindering AAV
transduction will aid in establishing methods to improve the efficiency of rAAV-mediated
gene delivery. In the present study, we have examined these steps in AAV6 mediated
transduction of mouse airway epithelia and have found that AAV6 is gifted with the unique
ability to escape the proteasome degradation pathway, which is responsible for its superior
transduction efficiency in mouse airways.
Results and discussion
AAV6 mediates efficient apical transduction in mouse airway epithelium in vitro
We have previously reported that the closely related AAV serotypes AAV1 and AAV6 were
able to transduce human airway epithelial cells (HAE) at higher efficiency than other natural
serotypes tested (Li et al., 2009). Here we compared their transduction efficiency on HAE
and on differentiated mouse airway epithelia (MAE) side by side with AAV1 and AAV6
packaging double strand GFP (AAV1GFP and AAV6GFP). AAV vectors were inoculated to
the apical surfaces of HAE/MAE at a dose of 1×1011 vg per culture (as optimized in the
previous study), and GFP transgene expressions were monitored over time. The numbers of
GFP-positive cells were found to reach maximum at 1 week post inoculation (p.i.) and
representative epifluorescence images are shown in Fig. 1a. Consistent with our previous
data, AAV6 showed higher transduction efficiency than AAV1 on HAE. Surprisingly,
AAV6 transduced significantly more cells on MAE than on HAE, i.e., about 30–50% for
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MAE to about 1–2% for HAE. AAV1 also transduced more cells on MAE (~5%) than on
HAE (<1%), although much less than AAV6. These results suggest that human and mouse
airway epithelia are very different in their susceptibility to AAV transduction from the
apical surface, and that different AAV vectors may be required for optimal gene transfer in
human or mouse airways. The finding is consistent with previous reports that the
efficiencies of different AAV serotypes on murine airways were not predictive of their
efficiencies on human airways (Flotte et al., 2009; Liu et al., 2006). To determine the cell
types targeted by AAV vectors in MAE, the transduced MAE cultures were immunolabeled
with a cilia specific marker (β-tubulin IV) followed by optical x-z confocal microscopy. As
shown in Figure 1b, both AAV1 and AAV6 transduced only lumen-facing columnar
epithelial cells including both ciliated and non-ciliated cells. Although the numbers of cells
transduced by AAV1 and AAV6 were different, their cellular tropism was similar. In
addition, we quantified the GFP mRNA levels in AAV transduced MAE by quantitative RT-
PCR (Fig. 1c). At one month p.i., the GFP mRNA level in AAV6 transduced MAE was
approximately one log higher than that by AAV1, consistent with the GFP fluorescence data
(Fig. 1a). The levels of GFP mRNA at 2 months p.i. were slightly lower than those at 1
month, confirming that AAV transduction in MAE is relatively stable.
To validate these results with AAV vectors containing double strand GFP transgene, we
next tested AAV vectors expressing a single strand luciferase transgene (AAV1luc and
AAV6luc). Both the apical or basolateral surfaces of MAE were inoculated with AAV1luc
or AAV6luc at 1×109 vg, and luciferase enzyme activities were measured at 2 weeks p.i.
(Fig.1d). Not surprisingly, transductions of both viruses from the basolateral surface were
about 30 fold higher than that from the apical membrane, even though AAV1 is reported to
transduce HAE from both surfaces equally (Yan et al., 2006). Consistent with the findings
for GFP-expressing vectors, the transduction efficiency of AAV6 is approximately one Log
higher than that of AAV1 from apical surface, likely due to the increased numbers of cells
targeted by AAV6.
AAV6 mediates efficient lumenal transduction in mouse airways and distal lungs in vivo
To investigate the transduction efficiency of AAV1 and AAV6 in mouse lower airways and
distal lungs in vivo, a single dose of 1×1011vg/mouse of AAV1GFP or AAV6GFP
expressing GFP were inoculated intratracheally in four mice per virus group. Mouse trachea
and lungs were harvested at one month p.i.; tissue sections were immuno-labeled with GFP
specific antibody to identify AAV transduced cells (green) with cell nuclei labeled with
DAPI (blue). Immunohistochemical analyses of mouse lungs for GFP expression revealed
that these two AAV vectors demonstrated similar targeting patterns of transduction for
conducting airway and alveolar epithelium though with different degrees of efficiency.
Representative photomicrographs of the tracheal, bronchiolus, and alveolar regions were
shown in Fig. 2a.Tissue sections were processed and are representative of four mice (Fig.
2a). A, B, C are AAV1 mediated GFP expression in alveoli, bronchiolus, trachea
respectively and D, E, F are AAV6 mediated GFP expression in alveoli, bronchiolus, trachea
respectively—As shown in Fig 2b, quantitation of the number of cells of the alveoli,
bronchiolus, trachea expressing GFP indicated that the transduction efficiency of AAV6 and
AAV1 of airway epithelia was significant different. AAV6 appears more efficient than
AAV1 in the airways. Both vectors showed similar efficiency in transducing both alveoli,
bronchiolus. In addition, both vectors were detected with much less frequently in the trachea
than in alveoli and bronchiolus. However, AAV6 demonstrated higher efficiency in the
trachea than AAV1.
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Sialic acid mediates AAV1&6 transduction in MAE, but can not account for the differences
in transduction efficiencies between AAV1 than AAV6
To elucidate the mechanisms responsible for the different transduction efficiencies between
AAV1 and AAV6, we first determined the binding properties of AAV on the apical surface
of HAE and MAE cultures. 5 × 1010 vg/culture (1.0 cm2) of AAV1 or AAV6 was incubated
on the apical surface of HAE or MAE for 2 hrs at 4 C. Unbound viruses were removed
followed by three washes with ice-cold DMEM. The numbers of AAV particles bound to the
epithelia were harvested and quantified with dot-blot assays (Fig. 3a). Densitometry analysis
(Fig. 3b) revealed that more AAV6 bound to HAE membrane than AAV1, consistent with
the finding that AAV6 transduced HAE better than AAV1 (Fig. 1a). However, in contrast to
the transduction data, the binding of AAV1 on MAE was significantly more than AAV6 (~
3 times more), suggesting that AAV virus binding to target cells (i.e., MAE) is not
proportional to virus transduction. In another word, the increased transduction of AAV6
than AAV1 is not due to the increased vector binding to MAE (the opposite is true). This
notion was further supported by the fact that AAV6 binds both HAE and MAE equally, yet
transduced MAE more than a log better than HAE. Therefore, the downstream steps must be
responsible for the difference in transduction efficiency between AAV1 and AAV6.
Since both AAV1 and AAV6 use α-2,3 and α-2,6 linked sialic acid as cellular receptors for
binding and transduction in non-polarized cells (Wu et al., 2006b), we examined the types
and distributions of sialic acids on the apical membrane of HAE and MAE using lectin
binding assays. Fluorescence (FITC) labeled sialic acid specific lectins, namely wheat germ
agglutinin (WGA, recognizes both α-2,3 and α-2,6 linked sialic acid), maackia amurensis
lectin (MAA, recognizes α-2,3-linked sialic acid), and sambucus nigra lectin (SNA,
recognizes α-2,6-linked sialic acid) were incubated at 10 μg/ml on the apical surface of HAE
and MAE, followed by three washes with DMEM. Fluorescent lectins bound to the apical
membrane were captured en face with fluorescence microscopy (Fig. 3c). The bindings of
WGA on both HAE and MAE indicated that the apical surfaces of both HAE and MAE are
extensively covered with sialic acid residues. Equal amounts of α-2,3 and α-2,6 linked sialic
acids are present on HAE (MAA and SNA bindings respectively). However, α2,3 linked
sialic acids appeared to dominate on MAE, similar to mouse airways in vivo. Taken together
with the AAV virus binding data, we speculate that AAV1 likely binds to α-2,3 linked sialic
acids, however, this interaction might not lead to productive transduction.
To determine the roles of sialic acids in AAV mediated transduction of MAE, we carried out
a lectin competition assay (Fig. 3d, 3e). AAV-luc vector (2×109 gc/culture) in the presence
of 100ug/ml WGA, MAA, or SNA were inoculated on MAE, and AAV transduction was
assayed by measuring luciferase activity at 2 weeks p.i. (Fig. 3d, 3e). Despite the difference
in AAV1 and AAV6 transductions, the degrees of reductions in the transduction efficiencies
by lectin competitions were similar between AAV1 and AAV6. WGA, which binds to sialic
acids of both α-2,3 and α-2,6 linkages, inhibited approximately 80% of the transductions for
both AAV1 and AAV6, suggesting that AAV1&6 transduction on MAE is mostly sialic
acid-dependent. MAA (α-2, 3-specific) blocked ~30% of transduction, whereas SNA (α-2,6-
specific) only blocked 15% of transduction by both AAV serotypes, likely due to the fact
that there are more α-2,3 than α-2,6 linked sialic acids on MAE (Fig.3c). These findings
demonstrate that AAV1 and AAV6 can utilize both α-2, 3 and α-2, 6 linked sialic acids as
the primary receptors for MAE transduction, and that sialic acids play a major role in AAV
mediated transduction in the airways for both AAV1 and AAV6 serotypes. Thus, the
requirement for sialic acid cannot possibly account for the differences in transduction
efficiencies between AAV1 and AAV6.
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Rate of AAV endocytosis can not account for the differences in the transduction efficiency
between AAV1 and AAV6 and between apical vs. basolateral inoculations
We next compared the rates of AAV internalization in MAE by measuring the amounts of
endocytosed AAV genome numbers using qPCR of Hirt DNA. MAE were inoculated with
equal amounts of AAV1-luc and AAV6-luc (MOI = 1 × 104) from either the apical or
basolateral side for 2 hrs followed by three washes with DMEM. Hirt DNA was extracted at
24 hr p.i. and the numbers of endocytosed vector genomes were quantified with qPCR (Fig.
4). For both AAV1 and AAV6, there was no difference in endocytosed AAV copies
between the apical and basolateral inoculations, which goes against our previous finding that
AAV transductions from the basolateral surface were 30-fold higher than from apical
membrane (Fig.1d). Furthermore, more AAV1 genomes were endocytosed than for AAV6,
whereas AAV1 transduction as measured by marker gene expressions (i.e., GFP and
luciferase) was at least 10-fold lower than that by AAV6. These findings suggest that the
difference in AAV vector internalization does not correlate with viral transduction and can
not account for the higher transduction efficiency of AAV6 than AAV1 or of basolateral
than apical inoculation. Attempts to separate the nuclear and cytoplasmic fractions of MAE
were not successful.
AAV6 has a unique ability at escaping the ubiquitin/proteasome degradation pathway in
mouse airway epithelia
The ubiquitin/proteasome pathway plays a role in AAV transduction of non-polarized cell
lines and differentiated human airway epithelia (Douar et al., 2001; Duan et al., 2000; Yan et
al., 2004). Since neither receptor binding nor vector endocytosis was responsible for the
enhanced AAV6 transduction over AAV1, we investigated the role of proteasome pathway
on AAV1 and AAV6 transduction. Using the same approach with proteasome modulating
agents on HAE (Li et al., 2009), MAE was inoculated from either the apical or basolateral
surfaces as before with AAV1luc or AAV6luc (MOI = 1×103) in the presence or absence of
40 μM proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (LLnL), and the
luciferase transgene expressions were assessed at 2 week p.i.. For apical transduction, the
treatment of LLnL significant increased the transduction efficiency of both AAV1 and
AAV6 (Fig. 5a). However, AAV1 transduction was increased by ~5-fold, versus ~2 fold for
AAV6. This suggests that AAV6 is less sensitive to proteasomal degradation compared to
AAV1. In another word, AAV6 maybe better equipped to escape the proteasome pathway
than AAV1.
The same trend holds true for basolateral transduction, except that it is ~30 fold higher than
apical transduction (Fig 5b). This suggests that AAV vectors endocytosed from apical or
basolateral surfaces were subjected to a common proteasome processing pathway, and that
both AAV1 and AAV6 were different in their sensitivity to proteasome degradation. We
conclude that AAV6 is unique in its ability to escape proteasome pathway, which is
responsible for its increased transduction efficiency in mouse differentiated airway
epithelium. Nonetheless, there was still significant enhancement of AAV6-mediated
expression in the presence of the proteasome inhibitor LnLL, suggesting that this capsid is
not totally resistant. Some or all of the six amino acid differences between AAV1 and
AAV6 capsid may be responsible for the interaction with the ubiquitin/proteasome factors,
which we are currently investigating.
Material and methods
Viruses and cells
Recombinant AAV vectors containing double stranded GFP (AAV1-GFP and AAV6-GFP)
driven by the chicken-β-actin enhancer and CMV promoter or single stranded Luciferase
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(AAV1-luc and AAV6-luc)) were produced using the triple plasmid transfection protocol as
described and virus titers were determined by dot-blot analysis (Xiao, Li, and Samulski,
1998). In vitro cultures of differentiated human airway epithelia (HAE) was generated as
described previously(Li et al., 2009) and cultures of differentiated mouse airway(trachea)
epithelial cells (MAE) was generated as previously described(You et al., 2002).
Transduction of MAE with Recombinant AAV Vectors
4–6 week-old MAE cultures were inoculated from the apical or basolateral surface with 100
μl of AAV vectors for two hours. The MOI varied from MOI of 1×103 to 1×105, as
indicated in the experiments. The proteasome modulating agent, N-acetyl-L-leucinyl-L-
leucinyl-L-norleucinal (LLnL) (40 μM) (Sigma), was mixed with AAV vectors before
inoculation when noted. Photomicrographs of transduced GFP-positive cells were acquired
using a Leica Leitz DMIRB inverted fluorescence microscope equipped with a cooled-color
charge-coupled device digital camera (MicroPublisher; Q-Imaging), and images of five
random fields for each MAE culture were captured. Ciliated cells were immunolabeled with
a β-Tubulin IV antibody (Sigma-Aldrich), followed by AlexaFluor594 conjugated goat anti-
mouse antibody (Invitrogen) as described previously (Zhang L, JV, 2005). Optical x-z
fluorescent confocal images were obtained using a Zeiss 510 Meta Laser Scanning Confocal
Microscope. In MAE inoculated with luciferase-expressing AAV vectors, luciferase
activities were measured using a luminometer (Perkin Elmer Life Sciences, Victor2 1420
Multilabel Counter).
AAV transductions in mouse trachea in vivo
C57BL/6 Mice (Jackson Lab.) were anesthetized with isoflorane and inoculated intra-
tracheally (i.t.) with 1×1011vg/mouse AAV1-GFP or AAV6-GFP in a volume of 50ul by
tracheal instillation. At 30 days p.i., mice were sacrificed and systemically perfused with
PBS. Lung and trachea were removed and fixed in 10% neutral buffered formalin overnight,
followed by equilibration in PBS containing 15% sucrose for 48 hr. Fixed tissues were
embedded in paraffin and tissue sections (5 m thickness) were subjected to the
immunofluorescence assay to identify AAV transduced cells, which were immunolabeled
with GFP-specific antibody (Sigma) followed by AlexaFluor568-conjugated secondary
antibody (red) (Invitrogen), whereas nuclei were stained blue with DAPI. Photomicrographs
of transduced GFP-positive cells were acquired as described previously.
AAV Binding Assays in vitro
AAV1-luc or AAV6-luc were inoculated to either HAE or MAE on the apical surface at 5×
1010 vg/transwell epithelium (1 cm2 surface area) at 4 °C for 2 h. Cells were then rinsed 3
times with PBS, and cell-associated AAV viral DNA was extracted by using DNAeasy kit
(Invitrogen). DNA samples were blotted onto a nylon membrane (Ambion) and AAV viral
DNA was detected with a P32-labeled Luc DNA probe. Viral genome number were
quantitated by dot-blot analysis(Xiao, Li, and Samulski, 1998).
Lectin Staining and Competition Assays
Lectin staining of the apical surface of HAE/MAE was performed by incubating the cells
with10 μg/ml FITC-labeled wheat germ agglutinin (WGA), maackia amurensis lectin
(MAA), or sambucus nigra lectin (SNA) (Vector Laboratories Inc.). Briefly, cells were
chilled to 4 °C, and 10 μg/ml lectin diluted in DMEM was added to the apical surface of the
epithelial cultures and incubated at 4 °C for 1 hour. Cultures were then rinsed three times
with DMEM, and fixed with 4% paraformaldehyde. Fluorescent photomicrographs of cell-
bound lectins were captured with a fluorescent microscope as described above. Lectin
competition experiments were done by pre-incubating cells with 100 μg/ml of WGA, MAA,
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or SNA at 4°C for 1 hour, followed by incubation with AAV6-luc (2×109 gc/transwell) in
the presence of 100 μg/ml respective lectin at 4°C for 2 hrs. Cultures were then rinsed three
times with DMEM at 4°C for 10 minutes each. Luc expression was determined two weeks
later with as described previously (Perkin Elmer Life Sciences, Victor2 1420 Multilabel
Counter) (Li et al., 2008).
AAV endocytosis Assay
MAE cultures were incubated at the apical or basolateral membrane with AAV1-GFP or
AAV6-GFP at the dose of 1×1010 gc/transwell for 2 hrs followed by three times of 10 min
washing to remove unbound virus. Cultures were returned to incubator for 22 hours to allow
AAV endocytosis. Low molecular weight Hirt DNA was extracted from infected cells as
described previously (Duan et al., 2000; Yan et al., 2004). The viral genome in the Hirt
DNA from endocytosed AAV was assessed by quantitative PCR (qPCR) performed on a
LightCycler 480 as previously described (Johnson and Samulski, 2009).
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Fig. 1. Transduction efficiencies of AAV1 and AAV6 in human and mouse airway epithelial
models in vitro
Human and mouse airway epithelial cultures (HAE and MAE respectively) were inoculated
apically with AAV1-GFP or AAV6-GFP at a dose of 1×1011 vg/culture (1.0 cm2 surface
area) (MOI = 1×105). Representative en face fluorescence photomicrographs showing GFP-
positive cells were obtained at 14 days post inoculation (p.i.). (a) Optical x-z confocal
images of MAE transduced with AAV1-GFP and AAV6-GFP showing AAV-transduced
cells as GFP positive. Cilia were immunolabeled with β-tubulin IV antibody (red) as
described in “Material and Methods”. (b) The apical surface of MAE was inoculated with
AAV1-GFP or AAV6-GFP (MOI of 5×104). The mRNA from MAE was harvested at 1 and
2 months p.i., and relative GFP mRNA copy numbers were determined with qRT-PCR (as
described in “Material and Methods”). Asterisk (*) denotes P<0.01. (c) AAV1-Luc or
AAV6-Luc at a dose of 109 gc/culture (1 cm2) was applied to either the apical surface or the
basolateral side of MAE and allowed to incubate at 37°C for 2 hrs. At 14 days p.i., luciferase
activities were assessed, and presented as the mean (± SEM) luciferase activity per cm2
epithelia (n=4). RLU, relative light units. Asterisk (*) denotes P<0.01.
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Fig. 2. AAV transduction of mouse airways in vivo
(a) Balb/c mice were inoculated by the intro-tracheal route with a single dose of 1×1011vg/
mouse in a volume of 50ul of AAV1-GFP (panels A, B and C) or AAV6-GFP (D, E, and F).
Mouse trachea and lungs were harvested at 1 month p.i.. Paraffin-embedded tissue sections
were prepared, and transduced cells were immunolabeled with rabbit anti-GFP antibody
(Sigma) followed by Alexafluor594- conjugated goat anti-rabbit antibody (Invitrogen).
Nuclei were stained blue with DAPI. Representative images for alveolar (A & D),
bronchiolus (B & E), and tracheal regions (C & F) are shown. (b) The numbers of GFP
positive cells per image field were quantified and the mean numbers from five random
images were shown (± SEM).
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Fig. 3. AAV transductions in HAE/MAE is sialic acid-dependent
(a) Relative AAV bindings to HAE and MAE. AAV1 or AAV6 at a dose of 5× 1010 vg/
culture (cm2) were allowed to bind to the apical surface of HAE or MAE and incubated at 4
C for one hour. Cell-associated AAV viral DNA was harvested from cell lysate and
quantified with dot-blot analysis (n=6). Densitometry was performed against a standard and
results are shown in (b). (c) The apical surface of HAE and MAE was probed with FITC-
labeled selective sialic acid-binding lectins: WGA (sialic acids of both α-2,3 and α2,6
linkages), MAA (α2,3-linked sialic acids), and SNA (α2,6-linked sialic acids) at 10 μg/ml
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concentration. Representative fluorescent photomicrographs were shown. (d) and (e) Lectin
competition assay. MAE cultures were pre-incubated on the apical surface with 100 μg/ml
of each lectin at 4°C for 1 hr. The lectins were then removed, and solutions containing 100
μg/ml lectin and AAV1-Luc (d) or AAV6-Luc (e) (MOI = 2×103) were inoculated.
Luciferase assay was performed at 14 days p.i., and the means (± SEM) were shown (n=4).
RLU, relative light units. Asterisk (*) denotes P<0.05.
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Fig. 4. AAV endocytosis at the apical and basolateral membranes
AAV1 or AAV6 at MOI of 1×104 was incubated with the apical or basolateral surfaces of
MAE cultures at 37ºC for 2 hrs, followed by washing with DMEM three times to remove
unbound virus. At 22 hrs p.i., Hirt DNA was extracted from infected cells and viral genome
copies were assessed by quantitative PCR (qPCR). Data represent the mean ± SEM (n=4).
Asterisk (*) denotes P<0.05.
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Fig. 5. Effects of proteasome pathway on AAV transduction of MAE
AAV1-Luc, AAV6-Luc were inoculated on either the apical surface (a) or the basolateral
side (b) of MAE cultures (MOI = 1×103) and incubated for 2 hrs at 37ºC in the presence or
absence of the proteasome inhibitor LLnL at the concentration of 40 μM. Relative luciferase
activities in relative light units (RLU) were assessed at 2 weeks p.i.. Data represent the mean
(± SEM) (n=4.). Asterisk (*) denotes P<0.05.
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